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ABSTRACT
DNA polymerase b (polb), a member of the X family of
DNApolymerases,isthemajorpolymeraseinthebase
excision repair pathway. Using in vitro selection, we
obtained RNA aptamers for polb from a variable pool
of 8 3 10
12 individual RNA sequences containing 30
random nucleotides. A total of 60 individual clones
selected after seven rounds were screened for the
abilitytoinhibitpolbactivity.Alloftheinhibitoryapta-
mers analyzed have a predicted tri-lobed structure.
Gel mobility shift assays demonstrate that the apta-
mers can displace the DNA substrate from the polb
active site. Inhibition by the aptamers is not poly-
merase specific; inhibitors of polb also inhibited
DNA polymerase k, a Y-family DNA polymerase.
However, the RNA aptamers did not inhibit the
Klenow fragment of DNA polymerase I and only had
aminoreffectonRB69DNApolymeraseactivity.Polb
and k, despite sharing little sequence similarity and
belongingtodifferentDNApolymerasefamilies,have
similarly open active sites and relatively few interac-
tions with their DNA substrates. This may allow the
aptamerstobindandinhibitpolymeraseactivity.RNA
aptamers with inhibitory properties may be useful in
modulating DNA polymerase actvity in cells.
INTRODUCTION
DNA polymerases (pols) replicate and maintain the integrity
of cellular DNA. As a consequence, DNA pols may play key
roles in both the avoidance and development of cancer (1). In
addition, since DNA pols are the target of many chemothera-
peutic agents, they may inﬂuence the efﬁcacy of the treatment
and possibly the development of resistance (1). DNA poly-
merase b (polb), a member of the X-family of low ﬁdelity
DNA pols, is the major gap-ﬁlling polymerase in both short
and long patch base excision repair (BER) pathways (2).
Polb is a distributive enzyme on long single-stranded tem-
plates (3) but acts processively on a gapped substrate (4).
Tumors and tumor cell lines where polb has been deleted
or truncated have decreased polb activity and therefore
impaired BER (5,6). It has been suggested that decreased
polb activity increases the susceptibility of individuals to can-
cer (7). High expression of polb has been seen in tumor cell
lines and is associated with increased mutagenicity, genetic
instability and tumorigenesis (8–10). Increased polb activity
also has been shown to increase tolerance to several chemo-
therapeutic agents including radiation, cisplatin and alkylat-
ing agents (8,11,12). The Y-family of DNA polymerases
are characterized by low ﬁdelity and are thought to be import-
ant in DNA damage tolerance pathways that involve transle-
sion synthesis (13,14). However, increased or uncontrolled
expression of error-prone DNA polymerases could lead to
mutations and cancer (1). In fact, alteration of Y-family poly-
merase expression levels appears to be common in tumors
(1). Although it is not clear whether overexpression of a
Y-family polymerase is causative in the initiation or progres-
sion of tumorigenesis, high expression of certain DNA pols
may provide cells with a growth advantage and/or resistance
to DNA damaging agents. In view of the tremendous import-
ance DNA pols play in human disease, the ability to modulate
DNA polymerase activity in cells would provide increased
understanding of their important role and could lead to the
development of new therapies.
RNA aptamers are RNA oligomers that bind tightly and
speciﬁcally to target molecules. Aptamers are selected
in vitro via SELEX (systematic evolution of ligands by expo-
nential enrichment) from randomized RNA libraries (15,16).
RNA aptamers are currently being developed as possible
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immunodeﬁciency virus type 1 (HIV-1) reverse transcriptase
(RT) have been explored as potential RT inhibitors to inhibit
HIV-1 replication (17–19). We decided to select RNA apta-
mers that would bind speciﬁcally to and inhibit the activity
of a DNA polymerase. Owing to the natural afﬁnity the poly-
merase has for nucleic acids, we expected that the aptamers
would bind to the polymerase active site and be highly spe-
ciﬁc inhibitors of enzymatic activity. We report here the
selection and characterization of RNA aptamers selected to
inhibit the polymerase activity of polb. Unexpectedly, the
aptamers also bind to and inhibit DNA polymerase k.
These semi-selective RNA aptamers that inhibit error-prone
repair polymerases could prove useful for understanding the
role of repair in the initiation and progression of cancer as
well as in the development of resistance to chemotherapeutic
DNA damaging agents.
MATERIALS AND METHODS
Oligonucleotides, RNA pools and target RNA
Template DNA for the RNA pool and PCR primers were syn-
thesized on a model 394 Applied Biosystems automated
DNA synthesizer. The preparation of the random RNA pool
has been described previously and shown to be a suitable lib-
rary for automatic SELEX (20). Brieﬂy, templates for reverse
transcription were synthesized by PCR using synthetic
oligonucleotides. The template was 50-GGGAATGGATCC-
ACATCTACGAATTC—30N—TTCACTGCAGACTTGAC-
GAAGCTT-30 where 30N represents 30 random nucleotide
positions. PCR primers were 50-GATAATACGACTCACTA-
TAGGGAATGGATCCACATCTACGA-30 and 50-AAGCT-
TCGTCAAGTCTGCAGTGAA-30, where the T7 promoter
sequence is underlined. RNA pools were prepared by in vitro
transcription with T7 RNA polymerase (Stratagene, La Jolla,
CA, USA). Pool RNAs were refolded by heat denaturing at
73 C and rapidly cooling to room temperature in binding
buffer (BB; 20 mM Tris–HCl, pH 7.7, 120 mM NaCl,
5 mM KCl, 1 mM MgCl2, 1 mM CaCl2).
Protein purification
DNA pols b (21) and k (22) were puriﬁed from over-
expressed Escherichia coli as previously described.
In vitro selection
To select the aptamers that bind to polb, seven rounds of
selection were performed. The aptamers were selected from
the random pool of the RNA sequences described above.
The ﬁrst four rounds of selection were carried out by ﬁltration
of the polb/RNA complex through nitrocellulose ﬁlters
(0.45 mm HA; Millipore, Billerica, MA, USA ). The ﬁlters
were washed with BB as described (23). Bound material
recovery from the ﬁlters, reverse transcription, PCR ampli-
ﬁcation of synthesized cDNA and RNA synthesis for the
next round of selection were performed as described (23).
Binding of the initial RNA pool to polb was close to the
background. In the ﬁrst round of selection, 100 pmol (200
nM) polb was incubated with 1.2 nmols (2.4 mM; 8 · 10
12
individual molecules) of variable RNA pool in 500 mlB B
(Table 1). In the next three rounds of selection, the amount
of the RNA was reduced to 500 pmol with the other condi-
tions remaining the same. In the ﬁfth and sixth rounds of
selection on nitrocellulose ﬁlters, the background binding of
the selected pool increased by >20%. Therefore, we went
back to the pool from the fourth round of selection and per-
formed the next three rounds of selection with polb adsorbed
to the surface of the immunological plates (Nunc Micro Well
Module, Nalgene Nunc, Rochester, NY, USA) (24). In the
ﬁfth and sixth rounds, wells were coated for 1 h at room tem-
perature with 50 pmol polb in 200 ml of PBS. After blocking
with Super Block Dry Blend (TBS) Blocking Buffer (Pierce
Chemical company, Rockford, IL, USA) (24) and washing
with BB, 200 ml of BB containing 150 pmol of the RNA
pool from the previous round was introduced into the wells
(Table 1). The wells were washed, bound RNA was
recovered and cDNA synthesized as described (24). In the
seventh round, the amount of polb introduced into the well
was reduced to 35 pmols (Table 1). The PCR products syn-
thesized after seventh round of selection were cloned into
the plasmid pGM-T (Promega, Madison WI, USA). Plasmid
DNA was puriﬁed (Miniprep Kit, Qiagen, Valencia, CA,
USA) and the sequence of the insert determined by automated
sequencing.
Determination of the affinity of selected pools
After completion of rounds 4–7, each pool was assayed for its
ability to bind polb. RNA pools were radiolabeled in a reac-
tion containing 40 mM Tris–HCl (pH 7.9), 25 mM MgCl2,
30 mM DTT, 2 mM each rNTP, 50 nM [a-
32P]UTP, 40 U
of RNAse inhibitor (Roche Applied Science, Indianapolis,
IN, USA), 120 U of T7 RNA polymerase (Stratagene,
La Jolla, CA, USA) and 45 pmol puriﬁed PCR product in a
total reaction volume of 100 ml (PCR Cleanup Kit, Qiagen,
Valencia, CA, USA). After 1 h of incubation at 37 C, the
labeled RNA was puriﬁed by electrophoresis on an 8% de-
naturing polyacrylamide gel (PAG) (23). Rather than
determining the binding constants of selected pools we
determined the minimal concentrations of polb at which the
binding of the complex of labeled RNA with protein was
detectable. After the fourth round of selection the binding
was minimally detectable at 100 nM polb. After the sixth
round, binding was detectable at 30 nM polb. After the
seventh round binding was well above background at 30 nM
polb. The pool selected after the eighth round had similar
binding to polb as the pool after the seventh round, so we
cloned the PCR products obtained after seventh round of
selection.
Table 1. Summary of the selection of polb aptamers
Round Polb (pmol) RNA pool (pmol) Method
1 100 1200 Filtration through nitrocellulose
2 100 500
3 100 500
4 100 500
5 50 150 Immunological plates
6 50 150
7 35 150
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in vitro analysis
Individual RNA aptamers were synthesized by in vitro tran-
scription from PCR products obtained by the direct ampliﬁca-
tion of bacterial lysates (25). In vitro transcription reactions
were performed in a mixture containing: 40 mM Tris–HCl
(pH 7.9), 25 mM MgCl2, 30 mM DTT, 2 mM each rNTP,
40 U of RNAse inhibitor (Roche Applied Science, Indiana-
polis, IN, USA), 200 U of T7 RNA polymerase (Stratagene,
La Jolla, CA, USA) and 70 pmol of puriﬁed (PCR Cleanup
Kit, Qiagen, Valencia, CA, USA) PCR product. The mixture
was incubated overnight at 37 C and the synthesized RNA
was puriﬁed by electrophoresis as described (23). After elu-
tion from denaturing PAG, the RNA was ethanol precipitated
and resuspended in 20 mlo fH 2O. Then 2 ml of 1M NaCl was
added, and the mixture was incubated for 3 min at 73 C and
cooled to room temperature. RNA concentration was determ-
ined using yeast transfer RNA (tRNA) (Roche Applied Sci-
ence, Indianapolis, IN, USA) as a standard (1 OD tRNA ¼
42 mg). The RNA was diluted in loading buffer (95% form-
amide, 0.1% bromphenol blue, 0.1% xylene cyanol 10 mM
Na-EDTA) and electrophoresed on a 10% denaturing
PAGE. The gel was stained with CYBR Green II and the
amounts of RNA quantiﬁed using a Storm 840 phosphorim-
ager (Amersham Biosciences Corp., Piscataway, NJ, USA)
and ImageQuant.
Kd determination of individual RNA aptamers
Individual RNA aptamers were radiolabeled in 40 mM
Tris–HCl (pH 7.9), 25 mM MgCl2, 30 mM DTT, 1 mM
each rNTP, 50 nM [a-
32P]UTP, 20 U of RNAse inhibitor
(Roche Applied Science, Indianapolis, IN, USA), 60 U of
T7 RNA polymerase (Stratagene, La Jolla, CA, USA) and
30 pmol of puriﬁed (PCR Cleanup Kit, Qiagen, Valencia,
CA, USA) PCR product for 1 h at 37 C in a total reaction
volume of 50 ml. The labeled RNA was used in the binding
assay without puriﬁcation. Radiolabeled RNAs (5 mli n
each binding reaction) were incubated in 100 ml BB with
increasing concentrations of protein. For binding curves, the
reactions were passed through individual 0.45 ml HA nitro-
cellulose ﬁlters (Millipore, Billerica, MA, USA) over DE
81 ﬁlter paper (Whatman, Florham Park, NJ, USA). In this
method, the nitrocellulose ﬁlter captures the protein-
bound radiolabeled RNA, while the DE81 paper captures
unbound radiolabeled RNA. The amount of radioactivity
retained at each protein concentration was quantiﬁed using a
Storm 840 phosphorimager (Amersham Biosciences Corp.,
Piscataway, NJ, USA) and ImageQuant.
Inhibition of DNA polymerase activity with
RNA aptamers
To detect the inhibition of the DNA polymerases, RNA apta-
mers were preincubated in 10 ml of 50 mM NaCl with DNA
polymerase at 37 C for 10 min. Then 10 ml of the solution,
containing 1–6 pmol (50–300 nM ﬁnal concentration) of
the oligonucleotide annealed substrate duplex [
32P-50-GGAA-
GAAGAAGTATGTT-30 50-CCTTCTTCATTCTAACA-
TACTTCTTCTTCC-30 32P-labeled and annealed as
described (26)]; 50 mM Tris–HCl (pH 7.5), 10 mM MgCl2,
10 mM DTT, 2 mg/mL BSA, 10% glycerol and 100 mM
dATP, dGTP and dTTP, were added to the DNA–
polymerase/aptamer mixture. After 10 min at 37 C, reactions
were placed on ice and an equal volume of loading buffer
(95% formamide, 0.1% bromphenol blue, 0.1% xylene cyanol
and 10 mM EDTA) was added to each tube. The products of
the polymerization reaction were separated on a 20% denatur-
ing PAG and analyzed using a Storm 840 phosphorimager
(Amersham Biosciences Corp., Piscataway, NJ, USA) and
quantiﬁed with ImageQuant. Time course assays were
performed similarly except that reaction time varied from 1
to 20 min.
Gel electrophoretic mobility shift assays
Competition between substrate DNA and aptamer binding
was determined for polb by a gel shift assay in which 500 nM
(or 700 nM) polb and 190 nM (or 250 nM)
32P-labeled 4-base
gapped substrate (27) were incubated in 10 mlB Ba t3 7  C for
15 min. Then varying amounts of puriﬁed aptamer RNA
(ﬁnal concentration: 0.5–1.4 mM) in 10 ml BB was added
and the mixture incubated another 15 min at 37 C. Finally
4 ml of 50% glycerol with 0.05% bromphenol blue was
added and the mixture electrophoresed on an 8% non-
denaturing PAG at 8 C for 1.5 h at 300 V. The gel was
analyzed using a Storm 840 phosphorimager (Amersham
Biosciences Corp., Piscataway, NJ, USA).
RESULTS AND DISCUSSION
In vitro selection of RNA aptamers that bind polb
For the selection of RNA aptamers that bind to and inhibit
polb, an RNA library of  8 · 10
12 different molecules was
generated with each molecule containing a 30 nt random
sequence ﬂanked by deﬁned sequences as described in the
Materials and Methods. Aptamers were obtained after four
rounds of selection on nitrocellulose ﬁlters and three rounds
of selection in the wells of immunological plates (Table 1).
After seven rounds of selection, the ampliﬁed cDNAs were
cloned.
Aptamers that inhibit polb activity
Since our selection was based on a general interaction
between the aptamer and polb, a further level of selection
was necessary to distinguish which of these aptamers could
inhibit polymerase activity. A total of 60 cloned aptamers
were screened in primer extension DNA polymerase assays.
To observe the level of inhibition, polb was pre-incubated
with two different concentrations of each individual RNA
aptamer. Once equilibrated, a
32P-labeled primed oligonuc-
leotide substrate and dNTPs were added, and the mixture
incubated to permit polb to extend the primer. A representa-
tive gel from the screening of eight individual cloned apta-
mers shows that at high aptamer concentration (480 nM),
all eight aptamers reduced the efﬁciency of primer extension
but only aptamers 32, 25 and 53 inhibited polymerase activity
at the 10-fold lower (48 nM) concentration (Figure 1). Apta-
mer 45 (data not shown) also inhibited polb at 48 nM. Of
the 60 aptamers tested, seven were good inhibitors of polb
(25, 32, 33, 41, 42, 45 and 53), about 35 aptamers slightly
inhibited DNA polymerase activity at high concentration
Nucleic Acids Research, 2006, Vol. 34, No. 9 2581similar to aptamers 12, 14, 17, 31 and 59, and the other apta-
mers showed virtually no ability to inhibit the polymerase
activity even at high concentrations (data not shown).
Anti-polb aptamers also inhibit DNA polymerase k
In order to determine the speciﬁcity of the polymerase inhibi-
tion, the individual aptamers were incubated with polk in pri-
mer extension assays under similar conditions to that used
for polb (Figure 2) except the aptamer concentration was
240 nM. As observed with polb, aptamers 32, 25 and 53 were
the most inhibitory, 12, 14 and 17 were moderately inhibitory
and 31 and 59 the least effective at inhibiting polk activity.
Aptamer 45 (data not shown) was also an effective inhibitor
of polk. All other aptamers analyzed had minimal effect on
polk activity and were not analyzed further.
Sequence of selected aptamers
Seven strongly inhibitory aptamers and a poor inhibiting
aptamer (aptamer 31) were sequenced. The eight aptamers
had ﬁve different RNA sequences (Figure 3). The most stable
two-dimensional structure of each RNA aptamer was pre-
dicted using MFOLD program (28,29) (Figure 3). In general,
two different folded structures are predicted from the selected
80 nt long aptamer sequences. In 4 of 5 cases, the aptamers
form a tri-lobed stem–loop structure with two long loops
and a short loop (Aptamers 25, 32, 45, 53). Loop 1 is com-
posed entirely of bases from the 50 constant region of the
aptamer and loops 2 and 3 are formed due to complementar-
ities between the constant and variable regions. All the inhib-
itory aptamers have loops 1 and 2 which are identical,
whereas loop 3 differs among the four aptamers. The other
structure (Aptamer 31) is predicted to form a bi-lobed stem–
loop structure. Loop 1, being formed from the constant region
is also present in Aptamer 31. The structure and sequence of
loop 2 is very different from the equivalent loop in the other
aptamers and loop 3 is missing. Further mutation studies of
these sequences will allow us to determine if the structure
or the sequence are more important for binding to and inhib-
iting the activity of DNA polymerases.
Affinity of aptamers for DNA polymerases
To evaluate binding speciﬁcities of these aptamers with polb
and polk, a nitrocellulose binding experiment was performed
using 50-radiolabeled RNAs (Figure 4A and B) and the values
of the dissociation constants (Kds) of RNAs were determined
(Figure 4C). We found that the aptamers selected for polb
binding also bound polk with similar afﬁnities (Figure 4B
and C). However, the maximum level of binding of aptamers
32 and 45 for polk are notably lower than that of aptamer 25.
Perhaps these aptamers fold into two or more slightly dif-
ferent conformations that interact with polk with different
afﬁnities.
RNA aptamers compete with primed oligonucleotide
substrate for binding
To elucidate the mode of aptamer binding, we analyzed the
ability of the aptamers to displace a bound primed oligonuc-
leotide template. Polb was incubated with a tight binding
4-base gapped oligonucleotide substrate (27) and varying
amounts of RNA aptamer. After a 15 min incubation, the
mixture was electrophoresed on a non-denaturing gel. Rep-
resentative results using aptamer 25 are shown in Figure 5.
However, all aptamers tested (25, 32, 45 and 53) were able
to displace the DNA bound in the polymerase active site at
similar aptamer concentrations (data not shown).
Figure 1. Inhibitionofpolbpolymeraseactivityby RNAaptamers.(A) Primer
extension reactions containing 4 nM polb and 300 nM 50-
32P-labeled primer-
templatewere performedasdescribedin Materialsand Methodsin the absence
(lane 2) or presence of 48 nM (lanes 4, 6, 8, 10, 12, 14, and 16) aptamer or
480 nM (Lanes 3, 5, 7, 9, 11, 13, 15) as labeled. Reactions were then quenched
and products were analyzed by denaturing PAGE. Lane 1 represents a control
reaction carried out in the absence of polb.( B) Bar graph showing quantifica-
tion of the polymerase activity in each reaction calculated by summing the
productofthebandintensityandthenumberofnucleotidesthathadbeenadded
to the primer under the assumption of completely distributive addition. This
valueforlane2,polbactivityintheabsenceofaptamerwassetto100%andthe
other lanes normalized to this value. For each aptamer, the black bars , 48 nM
and gray bars, 480 nM.
Figure 2. Inhibition of polk polymerase activity by RNA aptamers. Primer
extensionreactionscontaining8 nM truncatedpolk and 300 nM 50-
32P-labeled
primer-template were performed in the presence of 240 nM of each aptamer as
indicated. Reactions were then quenched and products were analyzed by
denaturingPAGE.In the left most lane ( ), the reactioncontained no aptamer.
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To determine if the selected aptamers inhibit DNA poly-
merases other than pols b and k, we assayed RB69 DNA
polymerase (RB69 pol, family B) and the Klenow fragment
of DNA polymerase I (KF, family A) from E.coli in the pres-
ence of two inhibitory aptamers, 32 and 45 (Figure 6A).
Yeast tRNA (up to 1 mM) only slightly reduced the extension
of the primer by polb and polk while aptamers 32 and 45
almost completely inhibited the polymerase activity. Apta-
mers 32 and 45 had a minor inhibitory effect on RB69 pol,
the effect being greater with aptamer 45. No inhibitory effect
of the aptamers were detected for KF. We also performed a
time course experiment showing dramatic inhibition of pols
b and k compared with the tRNA control (Figure 6B) by
aptamer 32. In the presence of 1 mM aptamer 32 polb has
20% remaining activity and polk, 26% compared with the
tRNA control condition. In contrast, we observed no inhibi-
tion of KF even at 4-fold higher concentrations of aptamer
32 (Figure 6B). Thus, the selected aptamers are most effect-
ive at inhibiting the lower ﬁdelity pols from the X and Y fam-
ilies and have little or no effect on the higher ﬁdelity pols
from the A and B families.
Structure of DNA polymerases may explain
low specificity of inhibitory aptamers
A number of RNA aptamer structures have been determined
by X-ray crystallography or NMR spectroscopy (30). These
structural analyses have been useful to generalize two types
of aptamers. High afﬁnity aptamers generated against pro-
teins that are potentially nucleic acid-binding proteins are
shorter in length and bind to their protein targets through a
small number of interaction sites. The major interactions
between the RNA and the protein are stacking of ﬂat moiet-
ies, hydrogen bonding and shape complementation (30). The
aptamers described here appear to bind directly in the poly-
merase active site, displacing the bound DNA substrate
(Figure 5). The Kds for the polymerase primer-template inter-
actions are as follows: RB69 pol, 70 nM (31), KF, 5 nM (32),
polb, 49 nM (primer-template) (33) and 48 nM [1-base
gapped template (34)], and the polk homolog (Sso DNA
pol Y1) has been reported to bind dsDNA with a Kd of
30 nM (35). From these approximate values one can conclude
that, among these four polymerases, KF has the strongest
interaction with primer-template DNA. If the mechanism by
which the aptamer binds the protein and inhibits polymerase
Figure 3. Sequences and structure of selected aptamers. (Upper) Sequences of the primers, the RNA pool and the polb aptamers. The PCR primer annealing sites
within the constant regions are underlined. For the RNA library, the randomized region (n30) is flanked by the 50 and 30 constant regions. The names of the
representativeaptamersareshownontheleft.Thenumberinparenthesesindicatesthenumberofindependentclonesoftheidenticalsequence.Inaptamer45,thelast
Cinthe50 constantregionhasbeenmutatedtoaU.ThesequencesareshownwiththemostsimilarsequencesgroupedtogetheraccordingtoClustal(49).(Lower)The
Mfold program (available at http://www.bioinfo.rpi.edu/applications/mfold) was used to derive secondary structural models for aptamers25 ( 17.6 kcal/mol, next
moststable 17.0kcal/mol),31( 15.3kcal/mol,nextmoststable 14.5kcal/mol),32( 19.3kcal/mol,nextmoststable 18.3kcal/mol),45( 21.2kcal/mol,next
most stable  20.6 kcal/mol) and 53 ( 20.2 kcal/mol, next most stable  19.4 kcal/mol). Only the most stable predicted structure is shown.
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tighter DNA binding of KF may partially explain the lack
of inhibition by the aptamers. The structures of the binary
(DNA–protein) complexes of these DNA polymerases have
been determined (36–39) (Figure 7). The interaction of KF
with primer-template DNA involves a large number of
amino acid residues and the protein wraps around the
bound DNA. In the polb structure, there are fewer interac-
tions and the DNA binding site is more open. RB69 pol
and polk are intermediate between these two extremes.
Perhaps a combination of substrate binding afﬁnity and the
‘openness’ of the active site determines whether these tri-
lobed aptamers inhibit the polymerase activity.
Comparison with other polymerase inhibiting aptamers
RNA aptamers have been selected that bind and inhibit
HIV-1 reverse transcriptase (40–44), yeast RNA polymerase
II (45) and E.coli RNA polymerase (46). In general, although
it has not been tested extensively, polymerase binding apta-
mers have been found to be speciﬁc. For instance, the
HIV-1 RT aptamers did not inhibit the reverse transcriptases
from Moloney murine leukemia virus or avian myeloblastosis
virus (43). The yeast RNA polymerase II aptamer did not
inhibit RNA polymerase I or III (45) and the E.coli RNA
polymerase aptamers did not bind to Taq RNA polymerase
(46). However, some of the HIV-1 RT inhibitory aptamers
Figure 4. Binding curves for RNA aptamers with polb and polk. Data points
were obtained by the nitrocellulose filter binding assay as described in the
Materials and Methods. (A) Polb, aptamer 25, circles; aptamer 32, squares
and aptamer 45, triangles. (B) Polk, aptamer 25, circles; aptamer 32, squares
andaptamer45,triangles.Ineachcase,theconcentrationofthelabeledaptamer
was 5–7 nM. C. Kds derived from the filter binding assays.
Figure 5. Aptamer 25 displaces bound primer-template from polb. Gel shift
competition reactions were carried out as described in Materials and Methods.
Each reaction contained 250 nM 4-base gapped DNA, 700 nM polb (except
lane2)andtheindicatedamountofpurifiedaptamer25;lanes1–3,noaptamer;
lanes 4–9, 6.0 mM, 3.0 mM, 1.5 mM, 0.75 mM, 0.38 mM and 0.19 mM. The
positionsoffreeandboundlabeledprimer-templatesareindicatedontheright.
Figure 6. Inhibition of DNA pols by aptamers 32 and 45. A. In reactions
containing polb (0.9 nM), polk (1.7 nM), RB69 pol (1.6 nM) or KF (1.1 nM)
and 50 nM 50-
32P-labeled primer-template, primer extension was measured in
the absence ( ) or presence of 300 nM aptamer 32, aptamer 45 or 1000 nM
yeast tRNA (T). (B) Time course reactions containing polb (0.3 nM), polk
(0.5 nM) or KF (0.3 nM) and 50 nM 50-
32P-labeled primer-template, primer
extension was measured in the absence ( ) or presence of 1–4 mM aptamer 32
or 1000 nM yeast tRNA.
2584 Nucleic Acids Research, 2006, Vol. 34, No. 9mimick primer-template junctions and could be extended by
the target polymerase RT as well as Sequenase (T7 DNA pol)
and AMV RT (47). The co-crystal structure of an RNA
pseudoknot bound to HIV-1 RT shows that the position of the
RNA aptamer bound to RT largely overlaps the DNA binding
site (48). It is likely that the polb aptamers we describe also
occupy the DNA binding site. The low polymerase selectivity
of the polb aptamers offers an advantage over highly speciﬁc
inhibitory aptamers in that they may be useful as generalized
DNA repair suppression molecules. Future experiments are
underway to express these aptamer in cells to explore this
possibility.
ACKNOWLEDGEMENTS
The authors thank Samuel H. Wilson for the polb overexpres-
sion plasmid and Haruo Ohmori for the bacterial expression
plasmid for truncated polk. The authors are indebted to
Margaret Luk-Paszyc for helpful discussions and critical read-
ing of the manuscript. This research was supported by grant
CA17395 from the National Cancer Institute to APG. Funding
to pay the Open Access publication charges for this article was
provided by the National Cancer Institute (grant CA17395).
Conflict of interest statement. None declared.
REFERENCES
1. Albertella,M.R., Lau,A. and O’Connor,M.J. (2005) The overexpression
of specialized DNA polymerases in cancer. DNA Repair, 4, 583–593.
2. Wilson,S.H. (1998) Mammalian base excision repair and DNA
polymerase beta. Mutat. Res., 407, 203–215.
3. Abbotts,J., SenGupta,D.N., Zmudzka,B., Widen,S.G., Notario,V. and
Wilson,S.H. (1988) Expression of human DNA polymerase beta in
Escherichia coli and characterization of the recombinant enzyme.
Biochemistry, 27, 901–909.
4. Singhal,R.K. and Wilson,S.H. (1993) Short gap-filling synthesis by
DNA polymerase beta is processive. J. Biol. Chem., 268, 15906–15911.
5. Husain,I., Morton,B.S., Beard,W.A., Singhal,R.K., Prasad,R.,
Wilson,S.H. and Besterman,J.M. (1995) Specific inhibition of DNA
polymerase beta by its 14 kDa domain: role of single- and
double-stranded DNA binding and 50-phosphate recognition. Nucleic
Acids Res., 23, 1597–1603.
6. Bhattacharyya,N., Chen,H.C., Wang,L. and Banerjee,S. (2002)
Heterogeneity in expression of DNA polymerase beta and DNA repair
activity in human tumor cell lines. Gene Expr., 10, 115–123.
7. Thompson,T.E., Rogan,P.K., Risinger,J.I. and Taylor,J.A. (2002)
Splice variants but not mutations of DNA polymerase beta are common
in bladder cancer. Cancer Res., 62, 3251–3256.
8. Canitrot,Y., Cazaux,C., Frechet,M., Bouayadi,K., Lesca,C., Salles,B.
and Hoffmann,J.S. (1998) Overexpression of DNA polymerase beta in
cell results in a mutator phenotype and a decreased sensitivity to
anticancer drugs. Proc. Natl Acad. Sci. USA, 95, 12586–12590.
9. Bergoglio,V., Pillaire,M.J., Lacroix-Triki,M., Raynaud-Messina,B.,
Canitrot,Y., Bieth,A., Gares,M., Wright,M., Delsol,G., Loeb,L.A. et al.
(2002) Deregulated DNA polymerase beta induces chromosome
instability and tumorigenesis. Cancer Res., 62, 3511–3514.
10. Servant,L., Cazaux,C., Bieth,A., Iwai,S., Hanaoka,F. and
Hoffmann,J.-S. (2002) A role for DNA polymerase beta in
mutagenic UV lesion bypass. J. Biol. Chem., 277, 50046–50053.
11. Bergoglio,V., Canitrot,Y., Hogarth,L., Minto,L., Howell,S.B.,
Cazaux,C. and Hoffmann,J.S. (2001) Enhanced expression and activity
of DNA polymerase beta in human ovarian tumor cells: impact on
sensitivity towards antitumor agents. Oncogene, 20, 6181–6187.
12. Raaphorst,G.P., Cybulski,S.E., Sobol,R. and Ng,C.E. (2001) The
response of human breast tumour cell lines with altered polymerase
beta levels to cisplatin and radiation. Anticancer Res., 21, 2079–2083.
Figure 7. Comparison of the DNA binding modes for DNA polymerase. Polb
binarycomplex (Protein Data Bank accession code 1BPX),DPO4 binary com-
plex(asafamilyYmodelstructure)(1N56),RB69polbinarycomplex(1Q9X),
KF(Bacillus)binarycomplex(1L3S).Theproteinresiduesareshowninagray
surfacerepresentation,theDNAprimerstrandingreenandthetemplateindark
blue. Figure was generated using PyMOL (50) (http://www.pymol.org).
Nucleic Acids Research, 2006, Vol. 34, No. 9 258513. Woodgate,R. (1999) A plethora of lesion-replicating DNA
polymerases. Genes Dev., 13, 2191–2195.
14. Ohmori,H., Friedberg,E.C., Fuchs,R.P., Goodman,M.F., Hanaoka,F.,
Hinkle,D., Kunkel,T.A., Lawrence,C.W., Livneh,Z., Nohmi,T. et al.
(2001) The Y-family of DNA polymerases. Mol. Cell, 8, 7–8.
15. Ellington,A.D. and Szostak,J.W. (1990) In vitro selection of RNA
molecules that bind specific ligands. Nature, 346, 818–822.
16. Tuerk,C. and Gold,L. (1990) Systematic evolution of ligands by
exponential enrichment: RNA ligands to bacteriophage T4 DNA
polymerase. Science, 249, 505–510.
17. Held,D.M., Kissel,J.D., Patterson,J.T., Nickens,D.G. and Burke,D.H.
(2006) HIV-1 inactivation by nucleic acid aptamers. Front Biosci., 11,
89–112.
18. Nickens,D.G., Patterson,J.T. and Burke,D.H. (2003) Inhibition of
HIV-1 reverse transcriptase by RNA aptamers in Escherichia coli.
RNA, 9, 1029–1033.
19. Joshi,P.J., Fisher,T.S. and Prasad,V.R. (2003) Anti-HIV inhibitors
based on nucleic acids: emergence of aptamers as potent antivirals.
Curr. Drug Targets Infect. Disord., 3, 383–400.
20. Sooter,L.J., Riedel,T., Davidson,E.A., Levy,M., Cox,J.C. and
Ellington,A.D. (2001) Toward automated nucleic acid enzyme
selection. Biol. Chem., 382, 1327–1334.
21. Conlon,K.A., Miller,H., Rosenquist,T.A., Zharkov,D.O. and Berrios,M.
(2005) The murine DNA glycosylase NEIL2 (mNEIL2) and human
DNA polymerase beta bind microtubules in situ and in vitro. DNA
Repair, 4, 419–431.
22. Ohashi,E., Ogi,T., Kusumoto,R., Iwai,S., Masutani,C., Hanaoka,F. and
Ohmori,H. (2000) Error-prone bypass of certain DNA lesions by the
human DNA polymerase kappa. Genes Dev., 14, 1589–1594.
23. Conrad,R.C., Giver,L., Tian,Y. and Ellington,A.D. (1996) In vitro
selection of nucleic acid aptamers that bind proteins. Methods
Enzymol., 267, 336–367.
24. Drolet,D.W., Jenison,R.D., Smith,D.E., Pratt,D. and Hicke,B.J. (1999)
A high throughput platform for systematic evolution of ligands by
exponential enrichment (SELEX). Comb. Chem. High Throughput
Screen, 2, 271–278.
25. Gening,L.V., Klincheva,S.A., Gusev,A.S., Surovoy,A.Y. and
Potapov,V.K. (2001) SSCP screening of individual aptamers.
Biotechniques, 31, 828–834.
26. Miller,H. and Grollman,A.P. (1997) Kinetics of DNA polymerase I
(Klenow fragment exo-) activity on damaged DNA templates: effect of
proximal and distal template damage on DNA synthesis. Biochemistry,
36, 15336–15342.
27. Miller,H., Prasad,R., Wilson,S.H., Johnson,F. and Grollman,A.P.
(2000) 8-oxodGTP incorporation by DNA polymerase beta is modified
by active- site residue Asn279. Biochemistry, 39, 1029–1033.
28. Zuker,M. (2003) Mfold web server for nucleic acid folding and
hybridization prediction. Nucleic Acids Res., 31, 3406–3415.
29. Mathews,D.H., Sabina,J., Zuker,M. and Turner,D.H. (1999) Expanded
sequence dependence of thermodynamic parameters improves
prediction of RNA secondary structure. J. Mol. Biol., 288, 911–940.
30. Hermann,T. and Patel,D.J. (2000) Adaptive recognition by nucleic acid
aptamers. Science, 287, 820–825.
31. Capson,T.L., Peliska,J.A., Kaboord,B.F., Frey,M.W., Lively,C.,
Dahlberg,M. and Benkovic,S.J. (1992) Kinetic characterization of the
polymerase and exonuclease activities of the gene 43 protein of
bacteriophage T4. Biochemistry, 31, 10984–10994.
32. Kuchta,R.D., Mizrahi,V., Benkovic,P.A., Johnson,K.A. and
Benkovic,S.J. (1987) Kinetic mechanism of DNA polymerase I
(Klenow). Biochemistry, 26, 8410–8417.
33. Werneburg,B.G., Ahn,J., Zhong,X., Hondal,R.J., Kraynov,V.S. and
Tsai,M.D. (1996) DNA polymerase beta: pre-steady-state kinetic
analysis and roles of arginine-283 in catalysis and fidelity.
Biochemistry, 35, 7041–7050.
34. Dalal,S., Kosa,J.L. and Sweasy,J.B. (2004) The D246V mutant of DNA
polymerase beta misincorporates nucleotides: evidence for a role for
the flexible loop in DNA positioning within the active site. J. Biol.
Chem., 279, 577–584.
35. Gruz,P., Pisani,F.M., Shimizu,M., Yamada,M., Hayashi,I.,
Morikawa,K. and Nohmi,T. (2001) Synthetic activity of Sso DNA
pol Y1, an archaeal DinB-like DNA polymerase, is stimulated by
processivity factors PCNA and RFC. J. Biol. Chem., 276,
47394–47401.
36. Sawaya,M.R., Prasad,R., Wilson,S.H., Kraut,J. and Pelletier,H. (1997)
Crystal structures of human DNA polymerase beta complexed with
gapped and nicked DNA: evidence for an induced fit mechanism.
Biochemistry, 36, 11205–11215.
37. Ling,H., Boudsocq,F., Woodgate,R. and Yang,W. (2004) Snapshots of
replication through an abasic lesion; structural basis for base
substitutions and frameshifts. Mol. Cell, 13, 751–762.
38. Freisinger,E., Grollman,A.P., Miller,H. and Kisker,C. (2004) Lesion
(in)tolerance reveals insights into DNA replication fidelity. EMBO J.,
23, 1494–1505.
39. Johnson,S.J., Taylor,J.S. and Beese,L.S. (2003) Processive DNA
synthesis observed in a polymerase crystal suggests a mechanism for
the prevention of frameshift mutations. Proc. Natl Acad. Sci. USA, 100,
3895–3900.
40. Joshi,P. and Prasad,V.R. (2002) Potent inhibition of human
immunodeficiency virus Type 1 replication by template analog reverse
transcriptase inhibitors derived by SELEX (Systematic Evolution of
Ligands by Exponential Enrichment). J. Virol., 76, 6545–6557.
41. Kensch,O., Connolly,B.A., Steinhoff,H.J., McGregor,A., Goody,R.S.
and Restle,T. (2000) HIV-1 reverse transcriptase-pseudoknot RNA
aptamer interaction has a binding affinity in the low picomolar range
coupled with high specificity. J. Biol. Chem., 275,
18271–18278.
42. Burke,D.H., Scates,L., Andrews,K. and Gold,L. (1996) Bent
Pseudoknots and novel RNA inhibitors of Type 1 human
immunodeficiency virus (HIV-1) reverse transcriptase. J. Mol. Biol.,
264, 650–666.
43. Tuerk,C., MacDougal,S. and Gold,L. (1992) RNA pseudoknots that
inhibit human immunodeficiency virus type 1 reverse transcriptase.
Proc. Natl Acad. Sci. USA, 89, 6988–6992.
44. Chaloin,L., Lehmann,M.J., Sczakiel,G. and Restle,T. (2002)
Endogenous expression of a high-affinity pseudoknot RNA aptamer
suppresses replication of HIV-1. Nucleic Acids Res., 30, 4001–4008.
45. Thomas,M., Chedin,S., Carles,C., Riva,M., Famulok,M. and
Sentenac,A. (1997) Selective targeting and inhibition of yeast RNA
polymerase II by RNA aptamers. J. Biol. Chem., 272,
27980–27986.
46. Kulbachinskiy,A., Feklistov,A., Krasheninnikov,I., Goldfarb,A. and
Nikiforov,V. (2004) Aptamers to Escherichia coli core RNA
polymerase that sense its interaction with rifampicin, sigma-subunit
and GreB. Eur. J. Biochem., 271, 4921–4931.
47. Schneider,D.J., Feigon,J., Hostomsky,Z. and Gold,L. (1995)
High-affinity ssDNA inhibitors of the reverse transcriptase of type 1
human immunodeficiency virus. Biochemistry, 34, 9599–9610.
48. Jaeger,J., Restle,T. and Steitz,T.A. (1998) The structure of HIV-1
reverse transcriptase complexed with an RNA pseudoknot inhibitor.
EMBO J., 17, 4535–4542.
49. Chenna,R., Sugawara,H., Koike,T., Lopez,R., Gibson,T.J.,
Higgins,D.G. and Thompson,J.D. (2003) Multiple sequence alignment
with the Clustal series of programs. Nucleic Acids Res., 31, 3497–3500.
50. DeLano,W.L. (2002) The PyMOL Molecular Graphics System.
2586 Nucleic Acids Research, 2006, Vol. 34, No. 9